CD8A and neoplasm: CDK4/6 inhibition with abemaciclib augments antigen presentation, upregulates IFN-stimulated genes, and promotes inflammation within the tumor microenvironment, thereby priming CD8+ T-cell infiltration; however, this inflammatory response may still be checked by PD-L1 upregulation.